Novavax XBB.1.5 COVID-19 Vaccine Adds Value

While the U.S. FDA issued various authorizations for mRNA COVID-19 vaccines yesterday, the only protein-based COVID-19 vaccine was included in the Advisory Committee on Immunization Practices (ACIP) meeting on September 12, 2023.

Dr. Filip Dubovsky, President Research & Development, Novavax Inc., presented updated data supporting the Novavax XBB.1.5 Vaccine.

This ACIP presentation included, but is not limited to, the following:

• Non-human primate data demonstrates that Novavax vaccine technology induces broadly neutralizing antibodies with primary vaccination,
• Neutralizing responses against XBB subvariants achieve levels comparable to homologous XBB.1.5 response,
• Consistent responses against all variants including emerging XBB subvariants.

In summary, Dr. Dubovsky stated during today's webinar that non-clinical data supports the use of the Novavax XBB.1.5 vaccine, there are robust neutralizing responses against XBB subvariants and data that generate a polyfunctional Th1-biased CD4+ cellular immune response against XBB subvariants.

Novavax COVID-19 vaccine brands include Nuvaxovid, CovoVax, and NVX-CoV2373, and has been distributed in about 40 markets as of September 2023.